Try

Enliven Therapeutics, Inc.

ELVNUnited States

26 filed reports · 357 financial concepts · 0 earnings calls · 0 media appearances

Filed reports

26 reports · Mar 2020 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR202,606Mar 2020 to Jun 2026
Annual · 10-KSEC EDGAR62,006Dec 2020 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 5, 2026292Open
FY2026 Q110-QMar 31, 2026May 7, 2026149Open
FY202510-KDec 31, 2025Mar 3, 2026537Open
FY2025 Q310-QSep 30, 2025Nov 12, 2025198Open
FY2025 Q210-QJun 30, 2025Aug 13, 2025123Open
FY2025 Q110-QMar 31, 2025May 14, 2025123Open
FY202410-KDec 31, 2024Mar 13, 2025338Open
FY2024 Q310-QSep 30, 2024Nov 13, 2024152Open
FY2024 Q210-QJun 30, 2024Aug 13, 2024126Open
FY2024 Q110-QMar 31, 2024May 14, 2024134Open
FY202310-KDec 31, 2023Mar 14, 2024331Open
FY2023 Q310-QSep 30, 2023Nov 9, 2023128Open

Financial data

357 concepts · 4,612 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial356 concepts · 4,606 facts · Dec 2018 to Jul 2026

  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value37 · Mar 2019 to Jun 2026
  • Allocated share based compensation expense37 · Mar 2019 to Jun 2026
  • Cash and cash equivalents at carrying value37 · Mar 2019 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents37 · Mar 2019 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect37 · Mar 2019 to Jun 2026
  • Comprehensive income net of tax37 · Mar 2019 to Jun 2026
  • General and administrative expense (US GAAP)37 · Mar 2019 to Jun 2026
  • Increase decrease in accounts payable37 · Mar 2019 to Jun 2026
  • Increase decrease in accrued liabilities and other operating liabilities37 · Mar 2019 to Jun 2026
  • Increase decrease in prepaid expenses other37 · Mar 2019 to Jun 2026
  • Net cash provided by used in financing activities37 · Mar 2019 to Jun 2026
  • Net cash provided by used in operating activities37 · Mar 2019 to Jun 2026
  • Net income loss37 · Mar 2019 to Jun 2026
  • Operating expenses (US GAAP)37 · Mar 2019 to Jun 2026
  • Operating income loss37 · Mar 2019 to Jun 2026
  • Research and development expense37 · Mar 2019 to Jun 2026
  • Share based compensation37 · Mar 2019 to Jun 2026
  • Stockholders equity (US GAAP)37 · Mar 2019 to Jun 2026
  • Accrued expenses and other current liabilities36 · Dec 2019 to Jun 2026
  • Interest income expense nonoperating net36 · Jun 2019 to Jun 2026
  • Nonoperating income expense36 · Jun 2019 to Jun 2026
  • Restricted cash36 · Jun 2019 to Jun 2026
  • Common stock par or stated value per share35 · Dec 2019 to Jun 2026
  • Common stock shares authorized35 · Dec 2019 to Jun 2026

Geography1 concepts · 6 facts · Dec 2024 to Dec 2025

  • Income taxes paid net6 · Dec 2024 to Dec 2025

Segments

6 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement geographical3 members · 6 facts

  • MA2 · Dec 2024 to Dec 2025
  • Other States2 · Dec 2024 to Dec 2025
  • US2 · Dec 2024 to Dec 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Enliven Therapeutics, Inc. (ELVN) data · FactIQ